Nkarta's pipeline updates show steady progress, but no major catalysts have emerged. Read what warrants a cautious outlook on ...

The six-year study focused on cyproheptadine, the active compound in the antihistamine Periactin. Periactin is commonly ...

Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in ...

The system can predict the risk of hepatocellular carcinoma recurrence with 82 per cent accuracy. Read more at ...

In connection with HekaBio’s recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen’s autologous NK cell ...

Funding in the amount of $2.0M from Japanese strategic investor, in the form of common equity PIPE with warrants. New funding provides for necessary resources to regain compliance with reporting oblig ...

Mesenchymal stem cell therapy lessens disability and brain lesions in MS patients, according to a review of published studies ...

A new class of South Korean immunotherapy drugs is raising hopes for a breakthrough in the treatment of a rare blood cancer ...

Avalon GloboCare Corp (NASDAQ:ALBT) saw its stock jump 16% following the announcement that it has been granted a standard ...

Investing.com -- Avalon GloboCare Corp (NASDAQ: ALBT) stock surged 16% after the precision diagnostic consumer products ...

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced the issuance of a new standard patent by the Hong Kong ...

MiNK Therapeutics surged 730% on breakthrough testicular cancer data with agenT-797. Click here to read my analysis on INKT ...